OPKO Health, Inc. (OPK)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$1.630.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge OPKO Health, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	145.48M
EPS	—	-0.068
Annual ending 2026-12-31
Revenue	—	569.9M
EPS	—	-0.227
Annual ending 2027-12-31
Revenue	—	495.1M
EPS	—	-0.305

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Increase gross profit above $45.8M	A supporting condition in OPKO Health, Inc.'s published investment case. The stated target is Gross profit > $45.8M.	Broken	Gross profit falls below $45.8M	Gross profit: $80.017M FY2026-Q2; GAAP. Published target: Gross profit > $45.8M. Target period is not explicitly aligned with this observation. Source published Jul 27, 202680,017,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 58f1a22c-cea5-467a-8c9f-a72de4600f57. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Gross profit grew from $49.4 million in 2025-Q2 to $80.0 million in 2026-Q2 and from $42.6 million in 2025-Q1 to $45.8 million in 2026-Q1. This indicates delivering progress in increasing gross profit as management has emphasized. Delivery assessment Oct 24, 2026
Improve operating income from negative levels	A primary condition in OPKO Health, Inc.'s published investment case. The stated target is Operating income improves from -$51M.	Broken	Operating income stays below -$51M or worsens	Operating income: $-6.972M FY2026-Q2; GAAP. Published target: Operating income improves from -$51M. Target period is not explicitly aligned with this observation. Source published Jul 27, 2026-6,972,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 58f1a22c-cea5-467a-8c9f-a72de4600f57. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Operating loss improved significantly from $60.0 million in 2025-Q2 to $7.0 million in 2026-Q2 and narrowed from $67.2 million in 2025-Q1 to $51.0 million in 2026-Q1. This shows delivering progress in improving operating income as management emphasized. Delivery assessment Oct 24, 2026
Achieve revenue of $530M to $560M in 2026	A primary condition in OPKO Health, Inc.'s published investment case. The stated target is >= $530M revenue.	Intact	Revenue falls below $530M in FY26	Revenue: $163.58M FY2026-Q2; GAAP. Published target: >= $530M revenue. Target period is not explicitly aligned with this observation. Source published Jul 27, 2026163,580,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 58f1a22c-cea5-467a-8c9f-a72de4600f57. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management set full year 2026 revenue guidance initially at $530M-$560M in 2026-Q1 and updated it to $560M-$585M in 2026-Q2. Actual revenue for first half 2026 was $287.8M, roughly on pace with guidance. The trajectory is delivering consistent with management's stated revenue targets. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

Unavailable → Unavailable · observed estimates

FY2027 revenue$0.50B

$0.57B → $0.50B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$565,833,940	1 / 6
2026-07-25	Unavailable	$565,833,940	1 / 6
2026-07-26	Unavailable	$565,833,940	1 / 6
2026-07-27	Unavailable	$565,850,000	4 / 5
2026-07-28	Unavailable	$565,833,940	1 / 6
2026-07-29	Unavailable	$585,433,940	2 / 6
2026-07-30	Unavailable	$585,433,940	2 / 6
2026-07-31	Unavailable	$585,450,000	4 / 5
2026-08-01	Unavailable	$585,450,000	4 / 5
2026-08-02	Unavailable	$585,433,940	2 / 6
2026-08-03	Unavailable	$585,433,940	2 / 6
2026-08-04	Unavailable	$588,950,000	4 / 5
2026-08-05	Unavailable	$588,972,850	2 / 6
2026-08-06	Unavailable	$588,972,850	2 / 6
2026-08-07	Unavailable	$588,950,000	4 / 5
2026-08-08	Unavailable	$588,972,850	2 / 6
2026-08-09	Unavailable	$588,972,850	2 / 6
2026-08-10	Unavailable	$588,950,000	4 / 5
2026-08-12	Unavailable	$588,950,000	4 / 5
2026-08-13	Unavailable	$588,950,000	4 / 5
2026-08-14	Unavailable	$588,950,000	4 / 5
2026-08-15	Unavailable	$588,950,000	4 / 5
2026-08-16	Unavailable	$588,950,000	4 / 5
2026-08-17	Unavailable	$588,950,000	4 / 5
2026-08-18	Unavailable	$588,950,000	4 / 5
2026-08-19	Unavailable	$588,950,000	4 / 5
2026-08-20	Unavailable	$588,950,000	4 / 5
2026-08-21	Unavailable	$588,950,000	4 / 5
2026-08-22	Unavailable	$588,950,000	4 / 5
2026-08-23	Unavailable	$588,950,000	4 / 5
2026-08-24	Unavailable	$588,950,000	4 / 5
2026-08-25	Unavailable	$588,950,000	4 / 5
2026-08-26	Unavailable	$588,950,000	4 / 5
2026-08-27	Unavailable	$588,950,000	4 / 5
2026-08-28	Unavailable	$588,950,000	4 / 5
2026-08-29	Unavailable	$588,950,000	4 / 5
2026-08-30	Unavailable	$588,950,000	4 / 5
2026-08-31	Unavailable	$588,950,000	4 / 5
2026-09-01	Unavailable	$588,950,000	4 / 5
2026-09-02	Unavailable	$588,950,000	4 / 5
2026-09-03	Unavailable	$588,950,000	4 / 5
2026-09-04	Unavailable	$588,950,000	4 / 5
2026-09-05	Unavailable	$588,950,000	4 / 5
2026-09-06	Unavailable	$588,950,000	4 / 5
2026-09-07	Unavailable	$588,950,000	4 / 5
2026-09-08	Unavailable	$588,950,000	4 / 5
2026-09-09	Unavailable	$588,950,000	4 / 5
2026-09-10	Unavailable	$588,950,000	4 / 5
2026-09-11	Unavailable	$588,950,000	4 / 5
2026-09-12	Unavailable	$588,950,000	4 / 5
2026-09-13	Unavailable	$588,950,000	4 / 5
2026-09-14	Unavailable	$588,950,000	4 / 5
2026-09-15	Unavailable	$588,950,000	4 / 5
2026-09-16	Unavailable	$588,950,000	4 / 5
2026-09-17	Unavailable	$588,950,000	4 / 5
2026-09-18	Unavailable	$588,950,000	4 / 5
2026-09-19	Unavailable	$588,950,000	4 / 5
2026-09-20	Unavailable	$588,950,000	4 / 5
2026-09-21	Unavailable	$588,950,000	4 / 5
2026-09-22	Unavailable	$588,950,000	4 / 5
2026-09-23	Unavailable	$588,950,000	4 / 5
2026-09-24	Unavailable	$588,950,000	4 / 5
2026-09-25	Unavailable	$588,950,000	4 / 5
2026-09-26	Unavailable	$588,950,000	4 / 5
2026-09-27	Unavailable	$588,950,000	4 / 5
2026-09-28	Unavailable	$588,950,000	4 / 5
2026-09-29	Unavailable	$588,950,000	4 / 5
2026-09-30	Unavailable	$588,950,000	4 / 5
2026-10-01	Unavailable	$588,950,000	4 / 5
2026-10-02	Unavailable	$588,950,000	4 / 5
2026-10-03	Unavailable	$588,950,000	4 / 5
2026-10-04	Unavailable	$588,950,000	4 / 5
2026-10-05	Unavailable	$588,950,000	4 / 5
2026-10-06	Unavailable	$588,950,000	4 / 5
2026-10-07	Unavailable	$588,950,000	4 / 5
2026-10-08	Unavailable	$588,946,983	4 / 5
2026-10-09	$-0.27	$588,950,000	5 / 5
2026-10-10	$-0.27	$588,950,000	5 / 5
2026-10-11	$-0.27	$588,950,000	5 / 5
2026-10-12	$-0.27	$588,950,000	5 / 5
2026-10-13	$-0.27	$588,950,000	5 / 5
2026-10-14	$-0.27	$588,950,000	5 / 5
2026-10-15	$-0.27	$588,950,000	5 / 5
2026-10-16	$-0.27	$588,950,000	5 / 5
2026-10-17	$-0.27	$588,950,000	5 / 5
2026-10-18	$-0.30	$495,100,000	5 / 5
2026-10-19	$-0.30	$495,100,000	5 / 5
2026-10-20	$-0.30	$495,100,000	5 / 5
2026-10-21	Unavailable	$495,100,000	4 / 5
2026-10-22	Unavailable	$495,100,000	4 / 5
2026-10-23	Unavailable	$495,100,000	4 / 5
2026-10-24	Unavailable	$495,100,000	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	3
2026-06-01	4	3
2026-07-01	4	2
2026-08-01	4	2
2026-09-01	4	2
2026-10-01	5	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

1 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 16

$4.00New observation · no comparable prior

BarringtonOct 16

$2.25New observation · no comparable prior

$0$2.20$4.40

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Increase gross profit above $45.8MPublished status: Broken
Improve operating income from negative levelsPublished status: Broken
Achieve revenue of $530M to $560M in 2026Revenue: $163.58M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-27.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

OPKO Health, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

OPK is a higher-risk recovery story, not yet a durable profit compounder, because it remains loss-making. The long-term thesis is intact, with recent progress in gross profit and operating losses, but confidence is medium.

What's priced into OPKO Health, Inc.

The evidence describes OPK as cheap versus peers, while the expectations gap is negative and model confidence is low. The valuation tag is justified, with low fragility, but ongoing losses make the peer comparison less conclusive.

What the fundamentals likely do

Near term, management has narrowed the operating loss and increased gross profit, while first-half revenue was roughly on pace with its updated 2026 guidance. The stated revenue priority is marked behind, so guidance delivery remains a risk; a guidance cut or weaker jobs data could also weigh on the business outlook.

What OPKO Health, Inc. hinges on

The multi-year view hinges on continued revenue delivery and further improvement in operating results. Near-term signals include whether management maintains guidance and whether healthcare peers keep reporting strong results; the recent agreement activity is positive, but the evidence gives few details on its impact.